188 related articles for article (PubMed ID: 37943223)
1. Tafamidis Efficacy Among Octogenarian Patients in the Phase 3 ATTR-ACT and Ongoing Long-Term Extension Study.
Garcia-Pavia P; Sultan MB; Gundapaneni B; Sekijima Y; Perfetto F; Hanna M; Witteles R
JACC Heart Fail; 2024 Jan; 12(1):150-160. PubMed ID: 37943223
[TBL] [Abstract][Full Text] [Related]
2. Long-Term Survival With Tafamidis in Patients With Transthyretin Amyloid Cardiomyopathy.
Elliott P; Drachman BM; Gottlieb SS; Hoffman JE; Hummel SL; Lenihan DJ; Ebede B; Gundapaneni B; Li B; Sultan MB; Shah SJ
Circ Heart Fail; 2022 Jan; 15(1):e008193. PubMed ID: 34923848
[TBL] [Abstract][Full Text] [Related]
3. Effect of long-term tafamidis treatment on health-related quality of life in patients with transthyretin amyloid cardiomyopathy.
Grogan M; Davis MK; Crespo-Leiro MG; Sultan MB; Gundapaneni B; Stedile Angeli F; Hanna M
Eur J Heart Fail; 2024 Mar; 26(3):612-615. PubMed ID: 38439606
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of tafamidis doses in the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR-ACT) and long-term extension study.
Damy T; Garcia-Pavia P; Hanna M; Judge DP; Merlini G; Gundapaneni B; Patterson TA; Riley S; Schwartz JH; Sultan MB; Witteles R
Eur J Heart Fail; 2021 Feb; 23(2):277-285. PubMed ID: 33070419
[TBL] [Abstract][Full Text] [Related]
5. Improved long-term survival with tafamidis treatment in patients with transthyretin amyloid cardiomyopathy and severe heart failure symptoms.
Elliott P; Gundapaneni B; Sultan MB; Ines M; Garcia-Pavia P
Eur J Heart Fail; 2023 Nov; 25(11):2060-2064. PubMed ID: 37434378
[TBL] [Abstract][Full Text] [Related]
6. Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy.
Maurer MS; Schwartz JH; Gundapaneni B; Elliott PM; Merlini G; Waddington-Cruz M; Kristen AV; Grogan M; Witteles R; Damy T; Drachman BM; Shah SJ; Hanna M; Judge DP; Barsdorf AI; Huber P; Patterson TA; Riley S; Schumacher J; Stewart M; Sultan MB; Rapezzi C;
N Engl J Med; 2018 Sep; 379(11):1007-1016. PubMed ID: 30145929
[TBL] [Abstract][Full Text] [Related]
7. Effect of Tafamidis on Cardiac Function in Patients With Transthyretin Amyloid Cardiomyopathy: A Post Hoc Analysis of the ATTR-ACT Randomized Clinical Trial.
Shah SJ; Fine N; Garcia-Pavia P; Klein AL; Fernandes F; Weissman NJ; Maurer MS; Boman K; Gundapaneni B; Sultan MB; Elliott P
JAMA Cardiol; 2024 Jan; 9(1):25-34. PubMed ID: 37966817
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of Tafamidis in Patients With Hereditary and Wild-Type Transthyretin Amyloid Cardiomyopathy: Further Analyses From ATTR-ACT.
Rapezzi C; Elliott P; Damy T; Nativi-Nicolau J; Berk JL; Velazquez EJ; Boman K; Gundapaneni B; Patterson TA; Schwartz JH; Sultan MB; Maurer MS
JACC Heart Fail; 2021 Feb; 9(2):115-123. PubMed ID: 33309574
[TBL] [Abstract][Full Text] [Related]
9. Long-term survival in people with transthyretin amyloid cardiomyopathy who took tafamidis: A Plain Language Summary.
Elliott P; Drachman BM; Gottlieb SS; Hoffman JE; Hummel SL; Lenihan DJ; Ebede B; Gundapaneni B; Li B; Sultan MB; Shah SJ
Future Cardiol; 2023 Jan; 19(1):7-17. PubMed ID: 36715498
[TBL] [Abstract][Full Text] [Related]
10. Causes of Cardiovascular Hospitalization and Death in Patients With Transthyretin Amyloid Cardiomyopathy (from the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial [ATTR-ACT]).
Miller AB; Januzzi JL; O'Neill BJ; Gundapaneni B; Patterson TA; Sultan MB; López-Sendón J
Am J Cardiol; 2021 Jun; 148():146-150. PubMed ID: 33667442
[TBL] [Abstract][Full Text] [Related]
11. Health impact of tafamidis in transthyretin amyloid cardiomyopathy patients: an analysis from the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR-ACT) and the open-label long-term extension studies.
Rozenbaum MH; Garcia A; Grima D; Tran D; Bhambri R; Stewart M; Li B; Heeg B; Postma M; Masri A
Eur Heart J Qual Care Clin Outcomes; 2022 Aug; 8(5):529-538. PubMed ID: 33895806
[TBL] [Abstract][Full Text] [Related]
12. Association of Tafamidis With Health Status in Patients With ATTR Cardiac Amyloidosis: A Post Hoc Analysis of the ATTR-ACT Randomized Clinical Trial.
Sperry BW; Hanna M; Maurer MS; Nativi-Nicolau J; Floden L; Stewart M; Wyrwich KW; Barsdorf AI; Kapadia H; Spertus JA
JAMA Cardiol; 2023 Mar; 8(3):275-280. PubMed ID: 36723935
[TBL] [Abstract][Full Text] [Related]
13. Improvements in Efficacy Measures With Tafamidis in the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial.
Hanna M; Fine NM; Gundapaneni B; Sultan MB; Witteles RM
JACC Adv; 2022 Dec; 1(5):100148. PubMed ID: 38939456
[TBL] [Abstract][Full Text] [Related]
14. Impact of Tafamidis on Health-Related Quality of Life in Patients With Transthyretin Amyloid Cardiomyopathy (from the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial).
Hanna M; Damy T; Grogan M; Stewart M; Gundapaneni B; Patterson TA; Schwartz JH; Sultan MB; Maurer MS
Am J Cardiol; 2021 Feb; 141():98-105. PubMed ID: 33220323
[TBL] [Abstract][Full Text] [Related]
15. Long-term tafamidis efficacy in patients with transthyretin amyloid cardiomyopathy by baseline left ventricular ejection fraction.
Drachman B; Damy T; Hanna M; Wang R; Angeli FS; Garcia-Pavia P
Eur J Heart Fail; 2024 Jun; ():. PubMed ID: 38932583
[TBL] [Abstract][Full Text] [Related]
16. Tafamidis and quality of life in people with transthyretin amyloid cardiomyopathy in the study ATTR-ACT: A plain language summary.
Hanna M; Damy T; Grogan M; Stewart M; Gundapaneni B; Sultan MB; Maurer MS
Future Cardiol; 2022 Mar; 18(3):165-172. PubMed ID: 34779246
[TBL] [Abstract][Full Text] [Related]
17. Estimating the Effect of Tafamidis on Cardiovascular-Related Hospitalization in NYHA Class III Patients with Transthyretin Amyloid Cardiomyopathy in the Presence of Death.
Li H; Rozenbaum M; Casey M; Sultan MB
Cardiology; 2022; 147(4):398-405. PubMed ID: 35853436
[TBL] [Abstract][Full Text] [Related]
18. Modeling of Survival and Frequency of Cardiovascular-Related Hospitalization in Patients with Transthyretin Amyloid Cardiomyopathy Treated with Tafamidis.
Vong C; Boucher M; Riley S; Harnisch LO
Am J Cardiovasc Drugs; 2021 Sep; 21(5):535-543. PubMed ID: 33770392
[TBL] [Abstract][Full Text] [Related]
19. Natural history and progression of transthyretin amyloid cardiomyopathy: insights from ATTR-ACT.
Nativi-Nicolau J; Judge DP; Hoffman JE; Gundapaneni B; Keohane D; Sultan MB; Grogan M
ESC Heart Fail; 2021 Oct; 8(5):3875-3884. PubMed ID: 34432383
[TBL] [Abstract][Full Text] [Related]
20. Effect of Tafamidis on Renal Function in Patients With Transthyretin Amyloid Cardiomyopathy in ATTR-ACT.
Sperry BW; Sultan MB; Gundapaneni B; Tai SS; Witteles RM
JACC CardioOncol; 2024 Apr; 6(2):300-306. PubMed ID: 38774010
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
